# **ASX ANNOUNCEMENT**



25 September 2024

# Board of directors strengthened with appointment of leading US healthcare executive

### Highlights:

- John H. Mathias II appointed as a Non-executive Director Mr Mathias has an accomplished career as an operations and business development executive in the healthcare sector including respiratory care and sleep management services
- Currently, he is the Chief Development Officer at Medbridge Healthcare, a premier provider
  of sleep lab management services and home sleep apnea testing in the US which performs over
  80,000 sleep diagnostic procedures annually. They collaborate with hospitals, healthcare
  systems, medical academic institutions, insurance companies, research entities, and directly with
  patients to deliver comprehensive, fully integrated solutions for sleep disorders.
- He also served as Chief Operating Officer and President of Sleep Services of America Inc., prior to being acquired by Medbridge and oversaw M&A, growth and leading business turnaround
- Appointment provides TRI with a further depth of expertise as it advances commercialization of its innovative, Al-backed algorithm MEB-001

**Perth, Australia, and Minneapolis, USA: TrivarX Limited** ('the **Company'**) (ASX: TRI) is pleased to advise that it has strengthened the composition of its Board with the appointment of Mr John H. Mathias II as a Non-executive Director, effective 1 October 2024.

Mr Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare, one of the largest sleep disorder diagnostic outsourced service providers in the US which performs over 80,000 sleep diagnostic procedures annually. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies.

Prior to his role as CDO, Mr Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability.

Throughout his career, Mr Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry.

# **ASX ANNOUNCEMENT**



Mr Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.

Non-executive Chairman, David Trimboli said: "It's my pleasure to welcome John to the Board at this important juncture in the Company's development and commercialization pathway. As we advance our strategy for regulatory approval and commercialisation for MEB-001, we continue to maintain dialogue with regulators, research partners and healthcare providers. In that context, John's extensive experience across the US health system, with a specific expertise in the operation of sleep diagnostic centres, is ideally suited to assist with both business development as well as logistics and planning for the potential application of our technology."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

#### **ENDS**

## **Investor Enquiries:**

Henry Jordan – Six Degrees Investor Relations <u>Henry.jordan@sdir.com.au</u> +61 431 271 538

#### **About TrivarX Limited:**

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on <a href="https://www.otcmarkets.com">www.otcmarkets.com</a> and <a href="https://www.asx.com.au">www.otcmarkets.com</a> and <a href="https://www.asx.com.au">www.otcmarkets.com</a> and <a href="https://www.asx.com.au">www.otcmarkets.com</a> and <a href="https://www.asx.com.au">www.otcmarkets.com</a> and <a href="https://www.asx.com.au">www.asx.com.au</a>